Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

(2021) Emma C Wall et al.   LANCET

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3

(2021) Ann R. Falsey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings

(2021) Mark G. Thompson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

(2021) Yinon M. Bar-On et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021

(2021) Ashley Fowlkes et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19–Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance — Nine States, June–August 2021

(2021) Shaun J. Grannis et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study

(2021) Noam Barda et al.   LANCET

Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine

(2021) Tal Patalon et al.   JAMA Internal Medicine

Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021

(2021) Peter J. Embi et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT